SAN DIEGO—(BUSINESS WIRE)—Feb. 6, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at the BIO CEO & Investor Conference 2007 on Tuesday,February 13, 2007, at 11:15 a.m. Eastern Time at The Waldorf=AstoriaHotel in New York City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website throughFebruary 27, 2007.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive clinical programs as well as a portfolio of preclinical anddiscovery assets directed at large unmet medical needs, includingschizophrenia, Parkinson's disease psychosis, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President andChief Financial Officer
858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.